Ion-Channel modulator TH1177 reduces glomerular injury and serum creatinine in chronic mesangial proliferative disease in rats
Open Access
- 19 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Nephrology
- Vol. 21 (1), 1-9
- https://doi.org/10.1186/s12882-020-01842-5
Abstract
T-type calcium channels (TTCC) are involved in mesangial cell proliferation. In acute thy-1 nephritis in the rat TTCC inhibition reduces glomerular damage and cell proliferation. This work is extended here by a study of the non-selective TTCC inhibitor TH1177 in a chronic model of proliferative glomerulonephritis (GN) including late treatment starting after the initial inflammation has resolved. The objective was to determine the effects of TH1177 in a model of chronic mesangioproliferative renal disease. Chronic GN was induced in WKY rats by unilateral nephrectomy (day − 7) followed by day 0 injection of Ox7 thy-1 mAb. Treatment with TH1177 (10–20 mg/Kg daily IP) was started on day 2 (early treatment) or on day 14 (late treatment) and compared to vehicle-treated controls until sacrifice at day 42. Glomerular disease was assessed with a damage score, fibrosis assay, cellular counts and renal function measured by serum creatinine. Treatment with TH11777 was associated with reduced serum creatinine, less glomerular damage, reduced fibrosis and reduced glomerular cellularity. The results for early and late TH1177 treatments were essentially the same and differed significantly from vehicle. The ion-channel modulator TH1177 is capable of improving glomerular outcome in chronic rat GN even when treatment starts 14 days after initiation of the disease. These data are discussed in the context of the possible targets of TH1177 including TTCC, TRP family, Stim/Orai group and other cation channels. The work supports the use of genetic models to examine the roles of individual cation channels in progressive glomerulonephritis to further define the targets of TH1177.Keywords
Funding Information
- Medical Research Council (TF2007)
- KRUK (RF2014)
This publication has 32 references indexed in Scilit:
- Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive ratsJournal Of Hypertension, 2010
- Comparative Effects of Benidipine and Amlodipine on Proteinuria, Urinary 8-OHdG, Urinary L-FABP, and Inflammatory and Atherosclerosis Markers in Early-Stage Chronic Kidney DiseaseThe American Journal of the Medical Sciences, 2010
- Inhibition of Human Mesangial Cell Proliferation by Targeting T-Type Calcium ChannelsNephron Experimental Nephrology, 2009
- Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic GlomerulonephritisHypertension Research, 2007
- Renal-Protective Effect of T- and L-Type Calcium Channel Blockers in Hypertensive Patients: An Amlodipine-to-Benidipine Changeover (ABC) StudyHypertension Research, 2007
- Blocking T-Type Ca2+ Channels with Efonidipine Decreased Plasma Aldosterone Concentration in Healthy VolunteersHypertension Research, 2006
- Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failureNephrology Dialysis Transplantation, 2005
- Low-Voltage-Activated (T-Type) Calcium Channels Control Proliferation of Human Pulmonary Artery MyocytesCirculation Research, 2005
- T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious ratsBritish Journal of Pharmacology, 1998
- Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized ratsClinical and Experimental Immunology, 1995